Last reviewed · How we verify
Desloratadine given orally
Desloratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration.
Desloratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration. Used for Allergic rhinitis (seasonal and perennial), Chronic idiopathic urticaria.
At a glance
| Generic name | Desloratadine given orally |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | H1-receptor antagonist (second-generation/non-sedating antihistamine) |
| Target | H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | Phase 3 |
Mechanism of action
Desloratadine competitively binds to peripheral H1 receptors on mast cells and basophils, preventing histamine release and its downstream effects on smooth muscle contraction, vasodilation, and itching. As a non-sedating antihistamine, it has minimal blood-brain barrier penetration due to its molecular structure and efflux by P-glycoprotein, resulting in reduced central effects compared to first-generation antihistamines.
Approved indications
- Allergic rhinitis (seasonal and perennial)
- Chronic idiopathic urticaria
Common side effects
- Headache
- Somnolence
- Fatigue
- Dry mouth
- Pharyngitis
Key clinical trials
- A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (PHASE3)
- An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desloratadine given orally CI brief — competitive landscape report
- Desloratadine given orally updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI